Response to lowering plasma glucose is characterised by decreased oxyntomodulin: Results from a randomised controlled trial

What Was Tested

The paper reports a study of Glucagon and Oxyntomodulin, published as a randomized controlled trial.

To investigate changes in plasma levels of PGDP in glycaemic responders versus non-responders.

Why It Was Studied

With the prevalence of diabetes reaching an epidemic level, there is a growing interest in the investigation of its remission.

However, whether they play a role in diabetes remission remains poorly understood.

Who Took Part

According to the abstract, 18 adults were involved.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

The study was a randomised placebo-controlled trial comprising 18 adults with prediabetes (registered at www.

How the Study Was Run

The researchers set it up as a randomized, placebo-controlled and crossover study.

The adults were allocated by chance, so the Glucagon group and the comparison group should start out alike.

The comparison arm used a placebo, so changes seen with Glucagon could be set against what happens without it.

Each person switched between Glucagon and the comparison at some point, usually with a gap in between.

What Was Measured

With the prevalence of diabetes reaching an epidemic level, there is a growing interest in the investigation of its remission.

The endpoints were changes in glucagon-like peptide-1 (GLP-1), glicentin, oxyntomodulin, glucagon, and major proglucagon fragment (MPGF).

Topics PubMed links to this paper include Oxyntomodulin, Blood Glucose, Biomarkers, Prediabetic State, Prognosis, Glucagon-Like Peptide 1 and Glucagon.

Author keywords: Diabetes remission, Glicentin, Glucagon-like peptide-1, Major proglucagon fragment and Proglucagon-derived peptides.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and crossover study of Glucagon and Oxyntomodulin in 18 adults.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Diabetes & metabolic syndrome), a journal based in Netherlands.

More context: the Glucagon compound page and the Oxyntomodulin compound page, all human trials.